Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary

November 9, 2026

NASDAQ US Health Care Pharmaceuticals earnings 41 min

Earnings Call Speaker Segments

Jennifer Good

executive
#1

Good afternoon, and thanks for joining our Q3 2026 earnings call and business update. Joining me today are Dr. James Cassella, our Chief Development Officer; Farrell Simon, our Chief Commercial Officer; and David Hastings, our Chief Financial Officer. Dave and I will make a few opening comments, and then the team will be happy to take any questions you may have. The company has a lot on its plate in 2026 when it comes to execution, and the team is fully focused on getting clinical trials underway and managing them for every one of our programs; that means opening sites globally, watching carefully to make sure enrollment remains on schedule, and staying in step with regulators throughout. Things have moved quickly, but this is the enjoyable side of our work. I'll share a quick update on each program. Starting with our main asset for chronic cough tied to IPF: both the OCEAN-1 and OCEAN-2 studies are now underway. Every regulatory body in the countries where we're running these trials has given approval, and our clinical group is concentrating on activating all sites and screening patients. Once each trial hits 50% randomized, we'll share an update. These studies remain at an early stage and are moving forward, and we still expect to meet the guidance we gave previously — for OCEAN-2, the 12-week trial, data in the second half of 2027, and for OCEAN-1, which measures efficacy at 24 weeks plus safety through 52 weeks, data in the first half of 2028. Back in October, we moved our non-IPF ILD cough program ahead significantly by reaching agreement with the FDA on the development plan and the next study. As we consider the path to securing the first U.S. approval for a chronic cough drug, the pulmonary division has offered substantial help and support. Those discussions were cooperative and straightforward. After that FDA meeting, we intend to run a phase II dose-ranging trial enrolling roughly 120 non-IPF ILD patients, which will let us confirm the optimal dose or doses to advance into phase III. The protocol has been drafted and will go back to the FDA for their feedback. We're already making progress on locating sites and collaborating with our CRO partner so that study initiation can be prepared. As a reminder, these clinical centers will overlap directly with the same sites being used in our North American IPF phase III program. At the time we signed the contract and negotiated budgets for our OCEAN trials, we accounted for the likelihood that we would run an ILD trial. Initiation of this trial is planned for the first quarter of 2027. Two doses of Haduvio will be studied over 12 weeks of fixed dosing in patients with interstitial lung disease, with IPF patients excluded. We expect top-line data to become available during the first half of 2028. Remember that ILD represents an opportunity over two times larger than the IPF potential, and doctors continue to describe a considerable unmet need within that population. In parallel with clinical work, we are reviewing prevalence and epi data so we can refine our estimates of the commercial opportunity in chronic cough unrelated to IPF. Turning to refractory chronic cough, or RCC, and our late phase IIb trial: because of the two rival drug failures this summer, I have discussed this program over recent months more than I ever expected to. Let me quickly summarize the current state of the RCC space and explain the forthcoming sample size re-estimation, or SSRE. To begin with, there are no active competing programs left in RCC — and, in fact, none in any of the chronic cough indications we're targeting. It's become clear that mechanisms acting only in the periphery can't cope with how complex and varied cough triggers are. Our thinking all along has been that while the peripheral mechanism does play a part in sensory signaling, the central mechanism is the critical one when it comes to lowering the hypersensitivity associated with cough. Next, people have asked me how market dynamics compare across RCC, IPF and non-IPF-related chronic cough. The fact is that RCC is an area of substantial unmet need, one where patients' quality of life takes a serious hit. We think that if the drug is able to provide relief for these patients, we can figure out the commercial side of things; we're looking at a range of options aimed at the most refractory patient group, possibly using lower doses, and so on. In a world where the patient comes first in everything, RCC is a serious chronic cough condition lacking any good treatment choices. Many brands, DUPIXENT among them, have shown they can successfully handle payer dynamics in larger follow-on indications. Lastly, as you're aware, developing drugs for RCC has proven quite difficult because of how heterogeneous chronic cough patients are, along with the placebo effect. We think our dual mechanism—acting both centrally and peripherally—gives us clear advantages, and the evidence we've gathered shows our drug works across a broad range of cough counts. Still, we're aware that positive trials have been quite rare. That's why, when we designed the phase IIb LAKE study, we incorporated a sample size re-estimation, or SSRE, to address variability in the patient population, the placebo effect, and similar factors. Let's briefly review how the analysis works. When 50%—that is, 50 patients—have completed the trial, an independent statistics team from outside Trevi will examine the unblinded data and verify the powering assumptions at that stage of the study. In essence, we'll get back one of three possible answers, with no accompanying data, so that the trial stays blinded. There are three possible paths forward. First, the study as it stands has at least 80% power, so we'd stick with the original enrollment target of 100 patients. Second, if the trial's conditional power falls between 40% and 80%, that tells us the drug is working, but either the variability is larger or the effect size is smaller than we first assumed. In that case, we'd enlarge the trial, up to a ceiling of 152 patients. This expansion isn't all or nothing — it's a proportional step of anywhere from four to 52 additional patients, meant to restore conditional power to at least 80%. Let me give you a bit of context on what that means. An effect size within this conditional power range works out to roughly the low 20% range up to 30%. To be clear, effect size means drug effect minus placebo. An effect size of 20%-30% is clinically meaningful and could matter a great deal in a setting where good options don't exist. And last, futility is the third possibility for the SSRE. Conditional power at the analysis point for the trial would come in under 40%, which would point to futility for the trial if fully completed. Given that the study will probably be near full enrollment and no competing programs remain, our plan would be to complete enrollment at the original sample size of 100 and review the data. Wrapping up what we covered on SSRE: with the SSRE design, a non-futile outcome would mean a clinically meaningful reduction in cough, and making the trial only somewhat larger helps guarantee that this clinical meaningfulness achieves statistical significance by the time the study ends. We expect SSRE findings to come in during the early portion of the first quarter, and our guidance for the complete trial results in the second half of 2027 has been reconfirmed. Finally, over the past month, a number of chronic cough patient advocacy organizations came together to hold an externally led patient-focused drug development, or PFDD, meeting with the FDA focused on the disease burden of chronic cough. During that session, individuals described the ways this condition impacts their daily existence, and what they recounted demonstrated how heavy a toll chronic cough takes on people dealing with IPF, ILDs, and RCC. An ILD patient remarked, "Cough is the single greatest thief of my quality of life." That gathering amounted to substantive dialogue with the FDA about elevating the urgency of having therapies that work and are safe. Results are scheduled to appear in 2027 through a Voice of the Patient report, and we are gratified that the FDA is paying attention to this considerable unmet need. To wrap up, our attention is on delivering against our strategy to become the leader in chronic cough. Given the recent setbacks our competitors have faced with RCC, we now have no rival in any of our three cough indications, and we could become a first-in-class treatment in markets that are very large. Our view is that by executing on the plan we have in place today, we can deliver meaningful value to patients and, as a result, substantial value to our shareholders. At this point I'll turn things over to Dave for his comments, and afterward we'll be glad to take your questions. Dave?

David Hastings

executive
#2

Thanks, Jennifer, and good afternoon, everyone. Today I'll concentrate on the financial measure we consider most important — our cash balance and the runway it gives us. We closed the third quarter of 2026 with roughly $299 million in cash equivalents and marketable securities. Crucially, we hold a strong capital position to carry out our development plans, since our cash runway reaches into 2030. That lets us finance our clinical trials up to key value inflection points, among them our lead program in IPF-related chronic cough, all the way through possible FDA approval. As Jennifer noted, we finished a positive FDA meeting recently, where we gained clarity regarding the clinical trial pathway for our non-IPF ILD-related chronic cough program. Given that feedback, our present cash runway covers funding that program through top-line data in our upcoming phase II trial. On top of that, our existing cash resources will completely fund our ongoing phase IIb LAKE trial for treating patients with RCC. The planned use of these cash resources also covers pre-commercial activities, yet it excludes any expenses tied to the commercial launch of Haduvio or a phase III clinical trial in RCC or non-IPF ILD; with that, I believe we are well-positioned to execute our clinical trials with sufficient funding through critical data points. Operator, we can now open the call for questions.

Roanna Ruiz

analyst
#3

Great, and hi, everybody. I was wondering if you could share more detail about that FDA meeting on ILD chronic cough. Did you get everything you were hoping for going in, and is there anything about the trial design we ought to keep in mind for the phase II dose-ranging study that matters especially when it comes to establishing the value proposition in this indication?

James Cassella

executive
#4

Hi, Roanna, Jim here. Appreciate the question; our meeting with the FDA went very well and they were very supportive. The main things we took away center on how the phase II dose-ranging trial will be designed, and it will resemble the CORAL study closely — the one we ran to get the IPF program started. The difference is that this trial will run longer, and that really backs a more complete phase III program. What the dose-ranging portion is really meant to do is let us confirm that in this different ILD population we have the same parameters for dosing and for dose selection. We ended up with really good alignment on what needs to happen there, and there was nothing unusual. Basically, it comes down to showing the data and showing which doses truly work in this particular population.

Roanna Ruiz

analyst
#5

Got it. If we look forward to a possible phase III study in ILD chronic cough, do you have any sense of where that might end up? Would it be one phase III trial, or is there anything you can share from what you've been hearing from the FDA?

James Cassella

executive
#6

There's one other point, I believe, that we've discussed some. Given that we need to factor in that this follows on from the IPF program, the regulatory pathway here will be an sNDA submission. We'll be drawing on the data gathered in the IPF ILD population to support the non-IPF ILD population in that program as we move forward. What's great about how we're approaching this, and the alignment we share with the FDA, is doing it stepwise so they can grasp what's required here and we can grasp what they're seeking. The phase II dose-ranging study is really meant to pin down the doses, gain experience in this patient population, layer that onto what we found and observed in the IPF population, and then craft the most efficient — hopefully, and I think realistically — single phase III trial that gets us to support the sNDA for non-IPF ILD.

Roanna Ruiz

analyst
#7

All right, thank you very much.

Annabel Samimy

analyst
#8

Hello, and thanks for the opportunity to ask. To build on the ILD study — it clearly resembles the IPF study quite closely. Has the FDA requested any additional work from you, or have you pre-planned further subgroup analyses for this population, since it may be somewhat more variable than the IPF population? Are you aiming to pinpoint distinct subgroups within your trial, or is that simply not feasible at this point?

James Cassella

executive
#9

Hello, Annabel. This is Jim once more. Thank you — that's an excellent question, and it's one we discussed at length with several KOLs in this area, because this is a diverse population. It's more heterogeneous than IPF. IPF represents the portion of the ILD world that is a more unified kind of population. Yet once we move into non-IPF, there are actually more than 100 different conditions involved; however, the underlying condition — fibrotic lung disease — is a shared thread across all of these patient groups; we intend to leverage the fact that they share this underlying lung condition, a certain amount of fibrosis, along with the cough. That, I believe, is the shared thread for all of these populations. We've had solid dialogue with the KOLs, and I think that's the approach we're taking here, because it's genuinely difficult when you examine all the various subgroups. A few of them are smaller, a few are larger. But really, we're going to get to the fundamental of the disease here, where the belief is that lung fibrosis is truly a significant underlying condition for the cough, and that will tie everything together.

Jennifer Good

executive
#10

The FDA did not focus on subgroups, right?

James Cassella

executive
#11

No.

Jennifer Good

executive
#12

Annabel, they were genuinely zeroed in on the fibrotic lung.

James Cassella

executive
#13

Yeah.

Jennifer Good

executive
#14

So, yeah.

Annabel Samimy

analyst
#15

Great. Okay, that helps. I have a single question about the RCC. The SSRE moved slightly into the first quarter, so I'm wondering about enrollment pace—that surprises me. Is enrollment just a bit slower? I hadn't expected it to be slower given some of the failures out there. Are there any ways to boost powering past 152 if you appear to be landing at the low end of the range? Could there be any possibility there regarding clinical effect size?

Jennifer Good

executive
#16

Well, I'll begin, and Jim, feel free to chime in.

Annabel Samimy

analyst
#17

Yeah.

Jennifer Good

executive
#18

Annabel, I think the timelines were always going to land this way — they consistently pointed to December. So when you say it slipped into Q1, that's early Q1; with the holiday, we're really talking about a matter of weeks here. Just for context, December was always a bit tricky, so it didn't take much for things to fall into January. As for whether there's any chance of going above 152 — Jim, you can weigh in on this — but we won't know within that 40%-80% range. All we'll know is that it's X and that you should upsize Y. I mean, we do always over-enroll a little, but no, we're not going to chase efficacy here. We're going to follow the recommendation.

James Cassella

executive
#19

Yeah, Annabel, I think we went in with certain powering assumptions. This is our first parallel arm study in RCC. We learned a lot from the RIVER study, which was the crossover in RCC, and we learned a lot from the CORAL study in terms of the IPF parallel arm study. I think the key point here is that we are powering sufficiently. This is a bit of a statistical adjustment given the effect sizes that we saw previously. So, we will take it with 80% power, which is appropriate for a phase II study. So, if we can get back up there, that is the end we will go with.

Annabel Samimy

analyst
#20

Okay. Got it. Thank you.

Jennifer Good

executive
#21

Thanks, Annabel.

Maxwell Skor

analyst
#22

Great, thanks a lot. Beyond the confirmation of powering, would the SSRE result alter your overall RCC planning? For instance, the target patient segment, the sizing of phase III, or whether you'd partner the program? Thanks very much.

Jennifer Good

executive
#23

We'll hold off until we see the complete data set. Honestly, Maxwell, the interim doesn't give us much beyond confirming powering in the end. We'll wait for the full data set. What I think has shifted here is that we're now in a world where nobody else is out there, and previously we were trying to be careful about showing superiority against any competing programs, but that's no longer the case. I think we'll take a careful look at the data, we'll speak with the agency, and we'll determine what our phase III program should look like. Much like Jim described for non-IPF ILD, we believe this is also an sNDA and may need only one phase III study. As for partnering, I don't think that's likely on the table, since we're a single asset company. We're going to want to keep global rights. Now, on the commercial side, whether we consider, Farrell, you can jump in, co-promotes or anything like that, I think certainly all those options are on the table. But our intent today is to retain commercial rights for our own program.

Maxwell Skor

analyst
#24

Great. Thank you.

Jennifer Good

executive
#25

Yeah. Thank you.

Leland Gershell

analyst
#26

Oh, excellent. Thanks for giving us this update and for taking our questions. We just have one, on the non-IPF ILD; so it sounds like the doses you'll be evaluating here effectively fall in line with what you've historically looked at in cough. I'm just wondering, perhaps for Jim, do you believe there's any biology that might lead to differences in response across that dose range compared with IPF ILD? Obviously, there's a lot of variability in the biology and in the diseases among the various other non-IPF ILDs. Just curious about your thoughts on the dose response in that non-IPF ILD. Thanks.

James Cassella

executive
#27

Yeah. No, thanks, Leland. That's a great question, and actually one that all of us were very interested in, especially the FDA, because it's all about doing definitive dose ranging. I think you can imagine that we have IPF, which is a very severe and terminal population. In the eyes of some, this may be a little different from that more IPF, more severe population. So, there's a possibility that you could see something working maybe a little bit better at the 27 mg dose strength; however, I think when we talk to the KOLs, their belief is that the fibrotic lung is driving all of this. So, this is really a study to demonstrate what we have and probably see something along the lines of what we saw with IPF. I think that really is, it's a show me stage to make sure that we have our doses right. I don't think we have a different expectation for ILD, but I think we'll get some good answers out of this.

Leland Gershell

analyst
#28

All right, thanks.

Ryan Deschner

analyst
#29

Hi there, appreciate the question, and congratulations on how far things have come. What I'd like to know is what lessons you've drawn from the GSK phase III setback involving camlipixant that might inform how you run the LAKE trial, or a later phase III effort for RCC, or even shape your view ahead of the upcoming SSRE update. Thanks.

Jennifer Good

executive
#30

Yes, thanks for asking, Ryan. As far as I know, nothing has been made public, so it has all reached us informally, though there has been a good deal of talk going around. From what investigators have told me, and from the company itself as well, my takeaway is that placebo likely wasn't a major issue in this case—which, as you know, has really always been the sole thing we had to worry about. I also think it sounds like their initial trial performed fairly well, and for some reason their second one, CALM-2, came apart. That was the longer study, but it was also enlarged twice, so there are quite a few confounding factors in play there. As Jim cautioned me from the outset, sticking with our own data is the better path, since those trials had plenty of complicating factors surrounding them. My sense is they were attempting to sort of enrich for people coughing more than 20 times. They enlarged the trial on two occasions. They kind of assumed control of the development program partway through. There were many difficult elements to that. Ryan, my expectation is that we will conduct our phase IIb, hopefully determine the dose, and then I hope we won't require a trial as large as everyone else has needed to run, because our effect size is going to be larger. That is roughly what we know. There's also the Nocion program that some folks know about — that drug simply failed. I've reviewed all the data. It didn't work in 2a, and I believe they ended up enrolling 400 patients just to demonstrate it didn't work in phase IIb. I don't think — I'm not sure, Jim. Nor did that trial teach me anything that felt particularly illuminating.

James Cassella

executive
#31

Right. Ryan, the important thing, I believe, is that the LAKE trial was built to provide exactly the information we require. Given what we've learned from chronic cough, from IPF, and from the RIVER data, I think we're able to steer our program using our own results, and we recognize that we truly must retain control over which centers we choose and which patients those centers choose, and we're on top of all of that.

Ryan Deschner

analyst
#32

Thank you very much.

Jennifer Good

executive
#33

Thank you, Ryan.

Wayne Wu

analyst
#34

Hello, team. Wayne here, filling in for Kaveri. Congratulations on everything you accomplished this quarter, and thank you for fielding our questions. From our discussions with certain investors, a few worries persist regarding how large the RCC market will ultimately be and how long it can last. What's your view on those worries, and which commercial programs and market development work do you feel will matter most for building physician awareness, finding the right patients, and achieving strong uptake of Haduvio once it's approved? Thanks.

Farrell Simon

executive
#35

Yes, Wayne, Farrell here. Thanks for asking. Looking at the RCC market, let me step back first; we are a company led by IPF/ILD. As we concentrate on developing that market, and those efforts are already underway through our unbranded campaign, we've reached, I believe, 93% of pulmonologists, who we've already engaged in conversations about the burden of chronic cough and that disease. Regarding what the RCC market could become, we will do our own proper sizing of it, but our estimate for the severe portion — those who have failed other therapies and who fit our inclusion/exclusion criteria of having a diagnosis for more than one year — is that this really narrows the market to roughly one million patients; those patients are primarily the ones pulmonologists will see. All of our efforts remain centered on pulmonology, and as for additional market development, that comes later in RCC, correct? Right now we are exclusively focused on building that IPF and ILD market.

Wayne Wu

analyst
#36

Understood. Many thanks.

Debanjana Chatterjee

analyst
#37

Hello there. Appreciate you fielding my question, and congratulations on everything you've achieved across the programs. My question concerns SSRE. Should the data warrant it, and the update points toward upsizing, what timeframe would be needed for enrolling the extra 52 patients, and in what way might that impact the top-line readout? I also have one brief follow-up.

James Cassella

executive
#38

Yes. Hello, Deb. Jim here. Our expectation is that, if we need to move to the complete cohort increase, we would still be in a position to report that readout before 2027 comes to a close.

Jennifer Good

executive
#39

Sorry, guidance would remain the same.

James Cassella

executive
#40

Yeah.

Jennifer Good

executive
#41

The second half of 2027. Yes.

Debanjana Chatterjee

analyst
#42

Okay, and I'm curious: to launch that as its own brand separate from the IPF program and keep differential pricing intact, how low would the RCC approvable dose have to be?

Farrell Simon

executive
#43

Hey, Deb and Johnny, Farrell here. That study will give us the dose. It's partly why we're testing 27 mg once daily. If we land in that range or below, it doesn't even necessarily have to be once a day. Even with really low doses in a twice-a-day delivery, we could still do that; we have work ahead to refine what the trial yields and truly grasp how that might affect IPF and ILD, since one thing we don't want is to cannibalize pricing in those indications.

Debanjana Chatterjee

analyst
#44

Thanks for the color on that. Appreciate it.

John Gionco

analyst
#45

Good afternoon, everyone. John here, filling in for Serge today. Thank you for the opportunity to ask a question. We've just got one for you today, and it concerns IP for Haduvio. I'm curious whether anything has changed in recent months that would reinforce Haduvio's patent protection, and what kinds of initiatives we might expect on that front as 2027 approaches.

Jennifer Good

executive
#46

Yes, John, thanks for raising that. It's been a major area of effort and attention across the company during this year. I mean, it's always been on our minds, but we've made a concerted push. As you'll see in the earnings release we just issued, we did in fact secure an additional patent covering dosing in hepatic impaired patients and non-IPF ILD. That extends that protection through 2041. So at its core, our patenting approach centers on method of use patents; we're working to establish the base patents for each of our indications. That carries protection through 2039, and past that point, we're filing essentially various dosing claims that have emerged from the work Jim's doing, along with different claims in the label. And we're having solid success getting those issued. So yes, we made some progress on that this quarter.

John Gionco

analyst
#47

Great. Appreciate the extra detail.

Jennifer Good

executive
#48

Yeah, thanks.

Brandon Folkes

analyst
#49

Hello, and thank you for taking my questions—congratulations on the progress made so far. I have maybe two questions regarding RCC. About the LAKE sample size re-estimation, could you explain how you handle potentially differing doses among the different responses—sorry, among the three active doses? Is the conditional power assessment for the SSRE based on the 54 mg arm, or on all three active arms? Second, if an upsize turns out to be necessary, do you gain any insight into whether effect size or variability is the cause? If so, could you help us consider variability alone—what that scenario looks like—given that you are testing lower doses? Thank you.

James Cassella

executive
#50

Yes. Hi, I'm Jim. Regarding the SSRE, it relies solely on the high dose—the 54 mg twice-daily dose—so everything we do will be driven by the analysis of that dose by itself. From the statisticians, we receive very little information. We will be told either to remain at our current N or to upsize by a certain number; we get no indication of what the issues are or what might be causing any kind of upsize. The entire point here is to keep us unbiased, and that is the purpose of this. It truly is a statistical adjustment; thus, to avoid biasing the trial, we receive very, very little information. Obviously, we will know all of it at the end of the day when the study completes, but along the way we do not get that information.

Brandon Folkes

analyst
#51

Great. Thanks a lot.

Conor MacKay

analyst
#52

Hello. Appreciate you taking my question, and congratulations on all the progress. I'm wondering whether you could talk about how enrollment is going for OCEAN-1 and OCEAN-2, and how you'd think about the timing for an eventual filing in IPF chronic cough. Could you submit the filing with only the OCEAN-2 data and add OCEAN-1 later on, or do you need both data sets in hand before you can < >

Jennifer Good

executive
#53

I'll take the first part of that. Jim, you add anything. Things are going well. We have a plan. I think site activations are coming along nicely; enrollment is coming along nicely. It's early. We think that we have reconfirmed our guidance, so we're comfortable with that as of now. I think I'd just add a little color. I've gone to all the investigator meetings that Jim and his team have hosted. There's a lot of excitement and enthusiasm around this clinical trial. As you guys probably know, there's been a lot of clinical work done in IPF, a lot of anti-fibrotic work, and I think there's genuine excitement around having a cough option for people to enroll in. So, yeah, I think we feel good about that. What was the second half of the question?

James Cassella

executive
#54

Really, on the filing strategy.

Jennifer Good

executive
#55

Yeah

James Cassella

executive
#56

We'd present the results from OCEAN-2 and OCEAN-1 as separate trial readouts, but the NDA itself would be a single comprehensive integrated submission. So that means reporting on each trial individually, plus there's integrated safety and integrated efficacy. All of it comes together at the end and gets filed as one piece for the clinical portion of the NDA.

Jennifer Good

executive
#57

Jim, if fast-tracked, filing could happen in sections. I realize they won't review any of it until the full set arrives.

James Cassella

executive
#58

They do not read anything until the thing is filed.

Jennifer Good

executive
#59

All right.

James Cassella

executive
#60

That doesn't really give us an advantage on any particular date, since nothing is settled until the final piece is in place.

Conor MacKay

analyst
#61

I appreciate the additional color there. Thanks.

James Cassella

executive
#62

Sure.

William Wood

analyst
#63

We appreciate you fielding our questions, and well done on another strong quarter. We've got a couple, one on ILD and another on LAKE; on LAKE, I wanted to ask if you could share anything about how site activation is progressing and whether it's remained on schedule or is now fully activated? And how many patients have in fact been enrolled so far? I recall you were anticipating the SSRE would read out at 50% completion, but I was wondering. Enrollment specifically, and then on ILD, could you remind us — you've now had some conversations with the FDA. We realize this isn't IPF, but is it still what's being ruled out of the study as far as its basket enabling goes? And then on dosing, why not a 27 once-daily dose? Is there some particular level of fibrosis or cough that will be required in this trial? Thank you.

Jennifer Good

executive
#64

Thanks, William. I'll handle the first part. I'll have Jim cover ILD. LAKE — our site activations remain on track. Not all sites are up and running, but we're a long ways there. That has gone very well. On the enrollment percentage, our standard approach will be to inform you once we reach 50%, with further updates provided afterward. Given that this has arrived somewhat early in the year, we're clearly making good progress. As soon as we get to that figure, you'll hear from us. Jim, I'll hand things over to you for all the ILD questions.

James Cassella

executive
#65

I might have missed the final one, so feel free to remind me. Regarding the approach to choosing patients, it will rest on a particular degree of fibrosis; that's going to be the foundational condition in this case. We aren't evaluating it by their individual comorbidities, but the goal is that essentially all the different comorbidities qualify, by and large, alongside the underlying fibrosis and chronic cough. I believe that was the last question. Sorry, you may need to remind me.

Jennifer Good

executive
#66

What is being excluded? Nobody is excluded, IPF.

James Cassella

executive
#67

Yeah. No, regarding ILD — I mean, honestly, the only people who get left out are those lacking that degree of fibrosis.

William Wood

analyst
#68

Could you

James Cassella

executive
#69

Was there one more? Yeah.

William Wood

analyst
#70

Yeah, just one quick follow-up on that. What level of fibrosis is required? I'm thinking about whether this is a moderate-to-severe cough trial where you only need to have fibrosis and meet some threshold, or whether there's a specific degree of fibrosis in the lungs—as opposed to just any amount—that patients have to fulfill or reach. And on dosing specifically, why not a 27 QD once-daily dose?

James Cassella

executive
#71

Yeah, regarding the fibrosis level, the KOLs in this space generally use a floor of at least 10% fibrosis in the IPF, non-IPF world to really establish a reliable condition. Then they break it out based on the HRCT scan and what type of ILD the patient may have. So we're thinking that we would require a minimum of about 10% lung fibrosis with no particular pattern. That sets the floor for us, and that's pretty much what the experts agree would establish an appropriate level of interstitial lung disease, whether IPF or non-IPF. So there's nothing magical there beyond setting the floor. On cough count, obviously patients have to have chronic cough over a period of time. So why not go to a 27 QD dose? Well, because in the IPF world, we saw that the 27 BID dose was our more effective dose. We're making the assumption that this non-IPF ILD program will follow very closely to the IPF program. We just didn't think that once a day 27 in the ILD space would be sufficient given the data that we have with IPF.

William Wood

analyst
#72

Understood. I appreciate it. Thank you for that, Mr. Cassella.

James Cassella

executive
#73

Certainly.

William Wood

analyst
#74

Thanks.

Jennifer Good

executive
#75

Thank you, William.

Jennifer Good

executive
#76

Thanks for being with us on today’s call. On Wednesday this week, we’ll be at the Stifel conference, and we hope to see a lot of you there. Thank you.

Operator

operator
#77

This concludes today's conference call. Thank you for attending. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.